Intravenous administration of Factor VIII - O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic protein

Hemophilia A is a bleeding disorder caused by the deficiency of an important coagulation factor; Factor VIII (FVIII). Replacement therapy using exogenously administered recombinant FVIII is the most commonly used method of treatment. However, approximately 30% of Hemophilia A patients develop neutra...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Eur J Pharm Sci
Hauptverfasser: Gaitonde, Puneet, Purohit, Vivek S., Balu-Iyer, Sathy V.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2014
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4404188/
https://ncbi.nlm.nih.gov/pubmed/25459532
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejps.2014.10.010
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge